ClinicalTrials.gg
RecruitingNCT07478952Updated Mar 24, 2026

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age

A Phase 1 interventional study of mRNA-1189 in Epstein-Barr Virus, sponsored by ModernaTX, Inc.. Recruiting at 2 sites in Australia. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies in Epstein-Barr Virus Infections with a site in Australia — 3 open to participants now, 5 under way, 2 of them phase 3. Epstein-Barr Virus Infections · Australia.

Started
2026
with 2 others
Phase 1
4 of 10
2 open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
ModernaTX, Inc.

Among the 10 studies in Epstein-Barr Virus Infections with a site in Australia, this one is one of 3 that started in 2026, is one of 4 in phase 1, and was the 8th registered.

Epstein-Barr Virus Infections

175 studies on the registry are indexed under Epstein-Barr Virus Infections; 60 are open to participants now.

Browse Epstein-Barr Virus Infections studies →

Open to participants now

3 of the 10 studies in Epstein-Barr Virus Infections with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 43 Epstein-Barr Virus Infections studies recruiting now, 23 (53%) set no upper age limit and 16 (37%) stop at 75 or younger; 23 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 30 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Epstein-Barr Virus Infections with a site in Australia, or all of them as a file.
02

Study summary

The main objective of this trial is to evaluate the safety and immunogenicity of mRNA-1189 after intradermal and intramuscular delivery.

03

Conditions studied

  • Epstein-Barr Virus

Keywords

  • Epstein-Barr Virus (EBV)
04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy as determined by medical evaluation including medical history and physical examination.
  • Participants who are assigned female at birth or could become pregnant are eligible to participate if the participant is not pregnant or breast/chest feeding.

Exclusion criteria

Exclusion Criteria:

  • Have undergone surgical procedures within 7 days prior to Day 1 or Day 57 or are scheduled to undergo a surgical procedure within 28 days after study intervention administration.
  • Reported history of congenital or acquired immunodeficiency, condition, asplenia, or recurrent severe infectious disease.
  • Received at ≥10 milligrams per day (mg/day) of prednisone or equivalent for >14 days in total within 90 days prior to Day 1 or is anticipating the need for corticosteroids at any time during the study.
  • Received systemic immunosuppressive treatment, including long-acting biological therapies that affect immune responses, within 180 days prior to Day 1 or plans to do so during the study.
  • Received or plans to receive any nonstudy vaccine from 28 days prior to first dose/Day 1 up to 28 days after the second dose/Day 57.
  • History of myocarditis, pericarditis, or myopericarditis prior to Day 1.
  • Has previously received an EBV vaccine.

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    mRNA-1189 Dose Level 1 (ID)

    Participants will receive 2 intradermal (ID) injections of mRNA-1189 at Dose Level 1 on Days 1 and 57.

    Biological: mRNA-1189

  • Experimental
    mRNA-1189 Dose Level 2 (ID)

    Participants will receive 2 ID injections of mRNA-1189 at Dose Level 2 on Days 1 and 57.

    Biological: mRNA-1189

  • Experimental
    mRNA-1189 Dose Level 1 (IM)

    Participants will receive 2 intramuscular (IM) injections of mRNA-1189 at Dose Level 1 on Days 1 and 57.

    Biological: mRNA-1189

  • Experimental
    mRNA-1189 Dose Level 2 (IM)

    Participants will receive 2 IM injections of mRNA-1189 at Dose Level 2 on Days 1 and 57.

    Biological: mRNA-1189

Interventions

  • BiologicalmRNA-1189

    Sterile liquid for injection

06

What researchers measure

Primary outcomes

  1. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)

    Time frame: Up to Day 64 (7-day follow-up after vaccination)

  2. Number of Participants with Unsolicited Adverse Events (AEs)

    Time frame: Up to Day 85 (28-day follow-up after vaccination)

  3. Number of Participants with Medically Attended Adverse Events (MAAEs)

    Time frame: Day 1 up to Day 225

  4. Number of Participants With Serious Adverse Events (SAEs), Any AEs Leading to Withdrawal From Study/Discontinuation of Study Vaccine and AEs of Special Interest (AESIs)

    Time frame: Day 1 to end of study (EOS) (Day 225)

Secondary outcomes

  1. Geometric Mean Titer of Antigen-Specific Binding Antibody (bAb)

    Time frame: Days 1 and 85

  2. Geometric Mean Fold Rise (GMFR) of Antigen-Specific bAb

    Time frame: Day 85

  3. Number of Participants With Seroconversion of Antigen-Specific bAbs

    Time frame: Day 85

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for May 2027, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Mar 18, 2026
StartActual
Mar 17, 2026
Primary completionEst.
May 15, 2027
CompletionEst.
May 15, 2027
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07478952
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Mar 18, 2026
Start date
Mar 17, 2026
Primary completion
May 15, 2027 (estimated)
Completion
May 15, 2027 (estimated)
Last update
Mar 24, 2026

Study contacts

Moderna WeCare Team
Contact
WeCareClinicalTrials@modernatx.com
1-866-663-3762

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion